These findings corroborate with previous findings that the use of combined anti HER2 treatment as well as the addition of a platinum drug to neoadjuvant chemotherapy is beneficial for breast cancer patients with these subtypes. This evidence concerns the gene ERBB2 and breast carcinoma.